These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24158996)

  • 1. Depleting T cells in newly diagnosed autoimmune (type 1) diabetes--are we getting anywhere?
    Lernmark Å
    Diabetes; 2013 Nov; 62(11):3669-70. PubMed ID: 24158996
    [No Abstract]   [Full Text] [Related]  

  • 2. The compelling case for anti-CD3 in type 1 diabetes.
    Skyler JS
    Diabetes; 2013 Nov; 62(11):3656-7. PubMed ID: 24158991
    [No Abstract]   [Full Text] [Related]  

  • 3. Otelixizumab in the treatment of type 1 diabetes mellitus.
    Sprangers B; Van der Schueren B; Gillard P; Mathieu C
    Immunotherapy; 2011 Nov; 3(11):1303-16. PubMed ID: 22053883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of type 1 diabetes mellitus to preserve insulin secretion.
    Herold KC
    Endocrinol Metab Clin North Am; 2004 Mar; 33(1):93-111, ix. PubMed ID: 15053897
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunotherapy: Modified proinsulin to treat T1DM.
    Geach T
    Nat Rev Endocrinol; 2013 Sep; 9(9):503. PubMed ID: 23856817
    [No Abstract]   [Full Text] [Related]  

  • 6. Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetes.
    Lachin JM; McGee PL; Greenbaum CJ; Palmer J; Pescovitz MD; Gottlieb P; Skyler J;
    PLoS One; 2011; 6(11):e26471. PubMed ID: 22102862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for Type 1 diabetes: getting beyond a negative first impression.
    Pozzilli P; Strollo R
    Immunotherapy; 2012 Jul; 4(7):655-8. PubMed ID: 22853748
    [No Abstract]   [Full Text] [Related]  

  • 8. Diabetes: Encapsulated β-cell implants enable glycaemic control.
    Greenhill C
    Nat Rev Endocrinol; 2016 Mar; 12(3):126. PubMed ID: 26846347
    [No Abstract]   [Full Text] [Related]  

  • 9. Lymphocyte transfusion in recent onset type I diabetes mellitus--a one-year follow-up of cell-mediated anti-islet cytotoxicity and C-peptide secretion.
    Krug J; Verlohren HJ; Bierwolf B; Lampeter E; Borte M; Nietzschmann U; Haustein B; Lohmann D
    J Autoimmun; 1990 Oct; 3(5):601-9. PubMed ID: 2252528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic transplantation.
    Dubernard JM; La Rocca E; Sanseverino R; Faure JL; Martin X; LeFrancois N; Finaz J; Gelet A; Touraine JL; Traeger J
    Adv Nephrol Necker Hosp; 1988; 17():363-73. PubMed ID: 3124548
    [No Abstract]   [Full Text] [Related]  

  • 11. Insulin secretion in type 1 diabetes.
    Steele C; Hagopian WA; Gitelman S; Masharani U; Cavaghan M; Rother KI; Donaldson D; Harlan DM; Bluestone J; Herold KC
    Diabetes; 2004 Feb; 53(2):426-33. PubMed ID: 14747294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DiaPep277® and immune intervention for treatment of type 1 diabetes.
    Schloot NC; Cohen IR
    Clin Immunol; 2013 Dec; 149(3):307-16. PubMed ID: 24090708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results.
    Eldor R; Kassem S; Raz I
    Diabetes Metab Res Rev; 2009 May; 25(4):316-20. PubMed ID: 19267355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes.
    Hannelius U; Beam CA; Ludvigsson J
    Diabetologia; 2020 Oct; 63(10):2177-2181. PubMed ID: 32754804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of an anti-CD5 immunoconjugate (CD5-plus) in recent onset type I diabetes mellitus: a preliminary investigation. The CD5 Diabetes Project Team.
    Skyler JS; Lorenz TJ; Schwartz S; Eisenbarth GS; Einhorn D; Palmer JP; Marks JB; Greenbaum C; Saria EA; Byers V
    J Diabetes Complications; 1993; 7(4):224-32. PubMed ID: 7693056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An improved clinical model to predict stimulated C-peptide in children with recent-onset type 1 diabetes.
    Buchanan K; Mehdi AM; Hughes I; Cotterill A; Le Cao KA; Thomas R; Harris M
    Pediatr Diabetes; 2019 Mar; 20(2):166-171. PubMed ID: 30556344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD3 clinical trials in type 1 diabetes mellitus.
    Daifotis AG; Koenig S; Chatenoud L; Herold KC
    Clin Immunol; 2013 Dec; 149(3):268-78. PubMed ID: 23726024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-peptide in the natural history of type 1 diabetes.
    Palmer JP
    Diabetes Metab Res Rev; 2009 May; 25(4):325-8. PubMed ID: 19267337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
    Herold KC; Gitelman SE; Ehlers MR; Gottlieb PA; Greenbaum CJ; Hagopian W; Boyle KD; Keyes-Elstein L; Aggarwal S; Phippard D; Sayre PH; McNamara J; Bluestone JA;
    Diabetes; 2013 Nov; 62(11):3766-74. PubMed ID: 23835333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Family incidence of latent autoimmune diabetes in adults--case report].
    Szepietowska B; Szelachowska M; Górska M
    Endokrynol Pol; 2006; 57(3):254-7. PubMed ID: 16832790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.